Coherus BioSciences, Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Coherus BioSciences, Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Coherus BioSciences, Inc. zu Deinem Portfolio hinzuzufügen.
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – – CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –
Coherus Oncology, Inc. (NASDAQ:CHRS ) UBS Virtual Oncology Day October 1, 2025 1:00 PM EDT Company Participants Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Dennis Lanfear - Chairman, President & CEO Rosh Dias - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Operator Welcome to the UB...
Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. The company could report readouts from its drugs in three indications in H1 2026: casdozokitug in hepatocellular carcinoma, CHS-114 in gastric cancer, and CHS-114 in head and neck cancer. There could be further readouts from CHS-114 in 2026 in esophageal squamous cell carcinoma and colorectal cancer.
Coherus Oncology remains a speculative play, with a strong cash position post-Udenyca sale and a cash runway into 2026 supporting ongoing pipeline development. Toripalimab sales are steady but limited by a small patient population, so financial viability hinges on the success of novel pipeline agents like casdozokitug and CHS-114. Pipeline risks are significant, as neither IL-27 nor CCR8 target...
Coherus Oncology, Inc. (NASDAQ:CHRS ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Bryan J. McMichael - Chief Financial Officer Dennis M.
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus' management team will host a conference call and webcast to discuss financial r...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.